Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-502 · 1 trial · 1 indication
Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe
| Arm | Type | Description |
|---|---|---|
| ATI-502 | EXPERIMENTAL | ATI-502 topical solution applied daily for four weeks. |
| Name | Type | Description |
|---|---|---|
| ATI-502 | DRUG | Topical Solution |
Inclusion Criteria: 1. Male or non-pregnant, non-nursing female subjects ≥ 18 years old at the time of informed consent. 2. Subject must have diagnosis of AD. 3. Subject must have a diagnosis of moderate or severe AD for a period of ≥6 months prior to the first dose of study medication. 4. Body sur...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ATI-502 is an investigational small molecule being developed as a topical solution for the treatment of atopic dermatitis, a form of eczema. It is currently in clinical development and has not been approved by the FDA.
ATI-502 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ACRS. The company is focused on dermatology treatments.
ATI-502 is in Phase 2 clinical development. A Phase 2 study of the topical solution for atopic dermatitis has been completed, but the drug remains investigational and is not yet approved for commercial use.
ATI-502 has one completed Phase 2 clinical trial, identified as NCT03585296, which studied the topical solution in 22 adult patients with atopic dermatitis in the United States. The trial was uncontrolled and not blinded.
No, ATI-502 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for atopic dermatitis, but it has not received regulatory approval and remains in clinical development.